A formidable foe: carbapenem-resistant Acinetobacter baumannii and emerging nonantibiotic therapies

Click to increase image sizeClick to decrease image size

Declaration of interest

R Watkins has received a grant and serves on an advisory board for Allergan. The authors has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

The manuscript was not funded.